Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia

被引:50
作者
Kumaki, F
Matsui, K
Kawai, T
Ozeki, Y
Yu, ZX
Ferrans, VJ
Travis, WD
机构
[1] Armed Forces Inst Pathol, Dept Pulm & Mediastinal Pathol, Washington, DC 20306 USA
[2] Natl Def Med Coll, Dept Pathol, Tokorozawa, Saitama, Japan
[3] Natl Def Med Coll, Dept Thorac Surg, Tokorozawa, Saitama, Japan
[4] Natl Inst Hlth, NHLBI, Pathol Sect, Bethesda, MD USA
关键词
D O I
10.1016/S0002-9440(10)63064-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
To investigate the association between the expression of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and the clinicopathological features in lepidic and invasive components of adenocarcinoma of the lung, we performed immunostaining for type IV collagen, various MMPs, and TIMPs in 27 cases of invasive adenocarcinomas and 5 cases of atypical adenomatous hyperplasia of alveolar epithelial cells (AAH). Mean extent of lepidic growth was 61% and the survival was significantly better in cases with 50% or more lepidic component. The preservation of type IV collagen in lepidic areas correlated inversely with lymphatic or vascular invasion (P = 0.02 and 0.002, respectively). Five-year survival was reduced in cases showing destruction of type IV collagen (P = 0.004) or expression of MMP-2 (P = 0.008) in lepidic areas. MMP-2 co-localized with MT-1-MMP (its activating enzyme) and TIMP-2 in neoplastic cells. Reactivity for other MMPs and TIMPs did not correlate with destruction of type IV collagen or prognosis. Type IV collagen was preserved in all cases of AAH. MMP-2, but not MT-1-MMP, was expressed in two of the five cases of AAH. immunostaining for type TV collagen MMP-2 is useful in evaluating the prognosis of the lung.
引用
收藏
页码:2125 / 2135
页数:11
相关论文
共 41 条
[1]  
[Anonymous], 1999, WHO INT HISTOLOGICAL
[2]  
AUERBACH O, 1979, CANCER, V43, P636, DOI 10.1002/1097-0142(197902)43:2<636::AID-CNCR2820430234>3.0.CO
[3]  
2-7
[4]  
BAKRIS GL, 1983, CANCER, V52, P493, DOI 10.1002/1097-0142(19830801)52:3<493::AID-CNCR2820520319>3.0.CO
[5]  
2-Y
[6]  
Bando E, 1998, ONCOL REP, V5, P1483
[7]   ACTIVITY OF TYPE-IV COLLAGENASES IN BENIGN AND MALIGNANT BREAST DISEASE [J].
DAVIES, B ;
MILES, DW ;
HAPPERFIELD, LC ;
NAYLOR, MS ;
BOBROW, LG ;
RUBENS, RD ;
BALKWILL, FR .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :1126-1131
[8]  
ELTORKY M, 1985, AM J PATHOL, V121, P322
[9]   Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions [J].
Galateau-Salle, FB ;
Luna, RE ;
Horiba, K ;
Sheppard, MN ;
Hayashi, T ;
Fleming, MV ;
Colby, TV ;
Bennett, W ;
Harris, CC ;
Stetler-Stevenson, WG ;
Liotta, L ;
Ferrans, VJ ;
Travis, WD .
HUMAN PATHOLOGY, 2000, 31 (03) :296-305
[10]  
GARBISA S, 1992, CANCER RES, V52, P4548